Abstract
Introduction

Ž .
The nanopeptide bradykinin BK has important actions on blood vessels, the heart and kidneys. By far the most important hemodynamic effect of BK in vivo is the vasorelaxation produced by endothelial release of nitric oxide, w x prostaglandins 1 and endothelium-derived hyperpolarizw x ing factor 2 . Bradykinin is also involved in pain reaction and can increase capillary permeability and produce edema w x 3 . BK, generated from kininogens by kallikreins is rapidly inactivated in blood and tissues by different amino and w x carboxypeptidases 4 . At least three of these enzymes are w x important from a pharmacological point of view 4 : an-Ž giotensin-converting enzyme ACE or kininase II, EC . 3.4.15.1 which acts as a dipeptidyl carboxypeptidase to remove the carboxy-terminal dipeptide Phe 8 
Ž
. endopeptidase NEP which cleaves the same bond in BK in vitro and in vivo as ACE to inactivate BK, and kininase I which removes Arg 9 residue from BK to produce the active metabolite des-Arg 9 -BK, an endogenous agonist of w x B kinin receptors 3 . 1 Several studies have shown that the ACE inhibitors protect the heart from tissue damage and arrhythmias w x caused by ischemia and reperfusion 5, 6 . This protective effect of ACE inhibitors could result from a reduction in local angiotensin II production or increased local bradykinin concentration secondary to inhibition of its catabolism. The latter hypothesis is supported by the fact that exogenous BK exerts a cardioprotective action in isolated hearts against the deleterious effects of w x ischemiarreperfusion 7 .
Ž . Neutral endopeptidase EC 3.4.24.11 is a metallopeptidase involved in the metabolism of several peptides such . as enkephalins, atrial natriuretic peptide ANP and BK w x w x 8 . It degrades also angiotensin I and II 8 and endothew x lins 9 in vitro and appears to participate in these prow x cesses in vivo 10 as well. This enzyme is located in the lungs, brain, intestine and the brush border of the renal w x proximal tubule 11 . NEP may also be located in rat w x mesenteric vascular bed 12 . This enzyme appears to be w x responsible for much of the ANP catabolism in vivo 13 w x and kinin catabolism in the kidneys 14 . Its contribution in BK catabolism in the coronary vascular bed is currently unknown.
Kinin metabolism in the heart is poorly understood. The aim of our study was to characterize the metabolism of BK after a single passage through the coronary bed in an isolated Langendorff rat heart and to assess the relative contribution of ACE and NEP in this metabolism. To study the enzyme involved in the carboxy-terminal metabolism of BK, an immunological method using highly specific polyclonal antibodies was used. To confirm that the measured immunoreactivity corresponds to the native BK, the aminopeptidase enzymatic activity in the metabolism of BK was assessed using high performance liquid chro-Ž . matography HPLC followed by immunoreactivity profile of the amino-truncated metabolites.
Interestingly, a recent study reported that a chronic treatment of rats with the AT -receptor antagonist, losar-1 w x tan, reduced ACE activity 15 . Therefore, the effect of losartan was compared with that of enzyme inhibitors.
Materials and methods
Animals and methods
Male Sprague-Dawley rats weighing between 275 and 300 g were used in the present study. Experiments were conducted according to the guidelines from the Canadian Council on Animal Care. Rats were anesthetized with sodium pentobarbital, 65 mgrkg body weight, injected intraperitoneally. The hearts were rapidly excised and im-Ž . mersed into ice-cold buffer containing heparin 20 UIrml before being perfused at constant flow rates through the aorta according to the Langendorff model. 
Ž .
HR was derived from the DLVP. These variables were Ž . recorded on a Nihon-Kohden Japan polygraph system. Hearts were allowed to stabilize for 20 min at 10 mlrmin. The experiments were performed with hearts perfused at either one of the following coronary flow rates: 1, 5 or 10 mlrmin. BK andror drugs were infused into the aortic flow line for 34 min to obtain a final concentration Ž . of 10 nM for BK 10 ngrml , 0.13 mM for enalaprilat, 25 nM for retrothiorphan and 1 mM for losartan. Five min before the drug infusion, the flow rate was either reduced to 5 mlrmin or 1 mlrmin or kept at 10 mlrmin. In the experiments performed at 1 and 5 mlrmin, flow rate was returned to 10 mlrmin for the last 7 min of drug infusion. Perfusate fractions of 2 ml were collected into tubes Ž containing ice-cold trifluoroacetic acid TFA, 100 ml of a . 10% solution per ml of perfusate under constant agitation.
Purification and quantification of BK and des-Arg 9 -BK from perfusate
The perfusate was purified by chromatography on C - 8 
Ž
. silica columns Waters, Milford MA, USA as described w x earlier 16 . The eluate containing kinins was evaporated to Ž dryness in a Speed Vac system Savant, Farmingdale NJ, . USA . The residue was dissolved in 500 ml of a Tris-HCl Ž . Ž . buffer 50 mmolrl containing Tween 20 0.5 mlrl and Ž . NaCl 100 mmolrl . Residual immunoreactive BK and formed immunoreactive des-Arg 9 -BK were quantified by a competitive enzyme immunoassay as previously described w x 16,17 . Both assays used highly specific polyclonal rabbit immunoglobulins raised against the carboxy-terminal end of BK and des-Arg 10 -kallidin, digoxigenin-labelled peptide as tracer, and alkaline phosphatase-labelled IgGs anti-digoxigenin with chemiluminescent substrate, LUMI-PHOS w Ž . Boehringer Mannheim, Germany to detect and quantify the immune complexes. On a molar basis, the polyclonal anti-BK purified IgGs exhibited no cross-reactivity with des-Arg 9 -BK. Likewise, anti-des-Arg 10 -kallidin IgGs showed no cross-reactivity with BK. Typical calibration curves were characterized by a half-maximal saturation value of 0.78 pmolrml for BK and 1.53 pmolrml for des-Arg 9 -BK. 
High performance liquid chromatography
Ž rated on a reverse phase column Vydac C 5 m, 4.6 = 250 18 . mm; Hesperia, CA, USA within 45 min, with a linear gradient from 80% solvent Ar20% solvent B to 65% solvent Ar35% solvent B at a constant flow rate of 0.7 mlrmin, and were detected at 214 nm. Solvent A was Ž . 0.025% heptafluorobutyric anhydride HFBA; volrvol in
. distilled water and solvent B was 0.025% HFBA volrvol in 90% acetonitrile y10% distilled water. Fractions of 0.7 ml were collected, evaporated to dryness in Speed Vac Concentrator and then frozen at y808C until immunoreactivity profile determination. BK and NH -terminal 2 metabolites were identified by comparison of their retenw x tion time with that of reference peptides 18 . This study of immunoreactivity profile was assessed at a coronary flow rate of 1 mlrmin, under which condition BK catabolism was maximal.
Volume of distribution of BK
The volume of distribution of BK was measured at 1, 5, w x and 10 mlrmin with a method adapted from 19 . Hearts were mounted and allowed to stabilize as described above.
. Boston MA was added to cold BK to obtain a final concentration in the heart of 10 nM BK with 10 000 DPMrml. This solution was infused for 5 to 6 min, which was enough to ensure that the radioactivity overflowing the heart had reached a plateau. The hearts were then removed from the perfusion setup, quickly rinsed in 10 ml Ž . KH buffer, and wiped dry. 50-mg samples in triplicates from the atria, the right ventricle, and the left ventricle Ž were digested in 0.5 ml hyamine hydroxide 1 M in . methanol at 508C for 24 h, and bleached with 0. 25 corrected for the heart mass. The statistical significance was evaluated using an analysis of variance followed by a Ž Tukey HSD post hoc test Systat for Windows, version . 6.1 . p -0.05 was considered statistically significant. 
Results
The concentration of BK in the perfusate before the infusion of exogenous BK was under the detection limit of the quantification method for every coronary flow rate, and did not rise above this limit in time-matched control experiment without infusion of BK either in the absence or Ž . presence of enzyme inhibitors data not shown . Reducing coronary flow rate from 10 to 1 mlrmin was accompanied Ž by changes in HR from 298 " 10 to 94 " 28 beatsrmin, . Ž . p -0.05 , CPP from 49 " 3 to 15" 4 mmHg, p -0.05 , Ž . and DLVP from 84 " 3 to 19" 2 mmHg, p -0.05 . These changes were less severe when flow rate was re-Ž duced from 10 to 5 mlrmin HR: from 300 " 10 to 211 " 18 beatsrmin, p -0.05; CPP: from 52 " 2 to 22" 2 mmHg, p -0.05; DLVP: from 75 " 3 to 27" 4 mmHg, . p -0.05 . Recovery of infused BK in the absence of inhibitors was related to the coronary flow rate: recoveries of 86.3 " 2.9%, 60.8 " 6.3% and 29.6 " 6.8% were mea-Ž . sured at 10, 5 and 1 mlrmin, respectively At 1 mlrmin, BK recovery in the presence of the ACE Ž inhibitor, enalaprilat, was significantly enhanced 59.9 " . 2.6%, Fig. 2 . The AT antagonist, losartan, did not mod-1 ify BK recovery. Inhibition of NEP with retrothiorphan also had no effect on BK recovery. However, the com- bined treatment with enalaprilat and retrothiorphan im-Ž . proved markedly BK recovery 81.2 " 5.2%, Fig. 2 . Qualitatively similar results but of reduced magnitude were Ž . observed at 5 mlrmin Fig. 3 . In contrast, BK recovery was unaffected by the enzyme inhibitors at 10 mlrmin Ž . Fig. 4 .
The effect of coronary flow rate and the different treatments on V rK is illustrated in Fig. 5 . V rK Ž . flow rate was restored to 10 mlrmin Fig. 5, panel Immunoreactive des-Arg 9 -BK could not be detected in the perfusate collected during these experimental conditions.
Discussion
The main actions of ACE are conversion of angiotensin I to angiotensin II and degradation of kinins. In the present study, we used an inhibitor to assess the contribution of ACE in the catabolism of BK following a single passage through the coronary bed. BK degradation was reduced in the presence of enalaprilat, which resulted in enhanced recovery at the lower coronary flow rates. These results suggest that kininase II plays an important role in BK catabolism in the coronary bed. The presence of the NEP inhibitor, retrothiorphan, had no effect on BK degradation and recovery. On the other hand, the combined treatment with enalaprilat and retrothiorphan was more efficacious than enalaprilat alone to inhibit BK degradation. Therefore, NEP contributes to the catabolism of BK only when ACE activity is inhibited. These results could be explained by differences in the V and K values of BK for ACE max m and NEP. For example, the K values of BK for human m ACE is much lower than that for NEP: K of BK for m human or rabbit NEP is 120 mM whereas that for ACE w x was estimated to be 1.0 mM 22 .
The relative proportion of ACE and NEP activities in the rat differs in several tissues such as the heart, the w x w x w x skeletal muscle 23 , the lung 24 and the kidneys 25 . For example, in the rat heart and skeletal muscles, ACE w x activity is higher than that of NEP 23 . In addition, it has been shown that ACE is a more important metabolic w x pathway of pulmonary BK than NEP 26 . Prechel et al. w x Ž . 21 demonstrated that the aminopeptidase P prolidase and ACE can fully account for the metabolism of BK in the pulmonary circulation and suggested that NEP is not involved in the pulmonary degradation of BK in vivo. NEP has been found immunocytochemically in lung epithelial cells but not in lung vascular endothelial cells that would w x be directly in contact with circulating BK 11 . However, NEP is responsible for 75% of renal BK metabolism in the rat. Although animal kidneys are generally very rich in w x ACE, the rat seems to be the exception 27 . ACE, mainly an endothelial enzyme, is responsible for BK metabolism within the vascular compartment, whereas NEP, mainly an epithelial enzyme, is involved in its catabolism in the kidneys. Yamada et al. have reported a heavy ACE labelling in rat coronary vessels by quantitative autoradiogw x raphy 28 . This concentration of ACE in rat coronary bed could explain the higher contribution of ACE in BK catabolism, compared with NEP, in our experiments.
Our study has demonstrated a clear effect of flow on BK recovery: higher flow rates were accompanied by a higher recovery. This cannot be due to an effect of flow on the enzymatic machinery since BK degradation rates were comparable in hearts perfused at 1 and 10 mlrmin. Rather, the effect of flow on BK recovery is likely due to transit time: at low flow, a longer time is needed for BK to travel through the coronary bed, resulting in a longer exposure of BK to the metabolizing enzymes. These observations suggest that coronary flow rate is an important factor to consider when studying the contribution of kinins in the cardioprotective effects of enzyme inhibitors like ACE inhibitors. In some groups, BK degradation rate in hearts perfused at 5 mlrmin was higher than in hearts perfused at either 1 or 10 mlrmin. This cannot be explained by change in the tissue distribution of BK at this particular flow rate since the VD measured at 5 mlrmin, although BK significantly lower than that at 1 mlrmin, was comparable to that at 10 mlrmin. Interestingly, the VD measured at BK 5 and 10 mlrmin were close to the extracellular space w x measured in the rabbit heart 19 . On the other hand, the higher VD at 1 mlrmin may be explained by a slight BK edema at this low flow rate. The active metabolite of BK, des-Arg 9 -BK, was not detected under our experimental conditions, even in the presence of enzyme inhibitors. This is in agreement with the small portion of BK metabolised into des-Arg 9 -BK Ž . w x 1.4% in rat serum 29 as well as in normal rat heart Ž . membranes 1%, unpublished data . However, these results w x contrast with those of Lamontagne et al. 30 who observed an enhanced release of des-Arg 9 -BK with enalaprilat upon reperfusion of the isolated rat heart following a 20-min total ischemia. Thus, BK metabolism in severely ischemic hearts differs from that of non-ischemic hearts. Although highly speculative, release of lysosomal enzymes capable 9 w x of forming des-Arg -BK 31 during ischemia may explain this discrepancy.
The AT antagonist losartan did not interfere with BK 1 metabolism in our study. These results are in agreement with those observed with normal rat heart membranes Ž . w x unpublished data . Schieffer et al. 15 have reported that a chronic treatment with losartan diminished the activity of cardiac ACE in hypertrophied rat hearts. Our result with an ( )acute administration clearly shows that this AT antagonist 1 does not interfere in the cardiac BK metabolism. This observation implies that the effect of a chronic treatment with losartan on cardiac ACE activity may be indirect and time-dependent. w x Ž Ryan et al. 32 identified a prolidase aminopeptidase . 1 2 P that cleaved the NH -terminal Arg -Pro bond of BK in 2 the pulmonary circulation, yielding an amino-terminal truncated peptide devoid of pharmacological activity. Since the antisera used in our analytical methodology recognises specifically the carboxy-terminal end of BK, we verified whether the measured carboxy-terminal immunoreactivity corresponded to native and pharmacologically active peptide. HPLC separation followed by immunoreactivity profile showed clearly that the measured immunoreactivity after a single passage through the coronary bed either with enalaprilat, with enalaprilat and retrothiorphan or without treatment, corresponded to more than 90% of native BK. Thus, the contribution of the aminopeptidase enzymatic activity was weak in our model. In conclusion, BK recovery during a single passage through the coronary bed is related to coronary flow rate, which is not due to change in degradation rates, but rather to different transit times. An important contribution of ACE to BK catabolism was observed in this model. NEP contributes to the degradation of BK only when the activity of ACE is impaired. The immunoreactivity profile of BK showed that the measured immunoreactivity in the perfusate with or without treatment corresponds to more than 90% of native BK. No significant contribution of kininase I could be observed.
